Neuroendocrine Tumors Treatment Market Trends

Neuroendocrine Tumors Treatment Market Drivers

A rise in the incidence of neuroendocrine tumors is expected to drive the market:

• The incidence and prevalence of neuroendocrine tumors (NET) are steadily rising worldwide, according to the data from the American Society of Clinical Oncology (ASCO). Because of this, the adoption rate of the medications for the treatment of this rare condition is aided by the rising prevalence of neuroendocrine tumors.

Extensive research and development to create new, focused medicines for NET management

• Over the course of the projection period, the market is anticipated to rise as more medications are approved for the treatment for neuroendocrine tumors. For instance, the U.S. Food and Drug Administration (FDA) approved Advanced Accelerator Applications' new drug application (NDA) for Lutathera (lutetium Lu 177 dotatate) for the treatment of adults with gastroenteropancreatic neuroendocrine tumors (GEP-NETs) that are Somatostatin receptor positive, including foregut, midgut, and hindgut neuroendocrine tumors.

Neuroendocrine Tumors Treatment Market Restraints

The risk of side effects following treatment and the high cost of NET therapy are anticipated to hinder market expansion

• Over the course of the projected period, the market expansion is anticipated to be hampered by the high cost of developing cures or pharmaceuticals and the adverse effects connected with the treatment. High blood sugar, the formation of gallstones, and moderate digestive system disturbances including bloating and nausea are among the potential adverse effects of therapies for neuroendocrine tumors.